Malaria is a major cause of mortality and morbidity globally. Great efforts have been made in the prevention and the elimination of malaria, especially in controlling the malaria vector, the mosquito. Another promising approach would be the development of malaria vaccines. Malaria vaccine studies can be focused on the pre-erythrocytic-stage antigens and the blood-stage antigens, and on the transmission blocking agents targeting the malaria gametocytes. The blood-stage antigens are the leading candidates in malaria vaccine development, as the blood-stage parasites are responsible for causing symptomatic malaria. Human acquired immunity largely targets on blood-stage antigens. This review focuses on one of the most extensively studied blood-stage antigen, the merozoite surface protein-1 (MSP-1), specifically on its evaluation and immunogenicity in rodents and primate models, and its safety and immunogenicity in human clinical trials.
Malaria Vaccines

The current status of malaria vaccine approaches has the background of a long and arduous path of malaria disease control and vaccine development. Here, we critically review with regard to unilateral interventional approaches and highlight the impact of socioeconomic elements of malaria endemicity. The necessity of re-energizing basic research of malaria life-cycle and Plasmodium developmental biology to provide the basis for promising and cost-effective vaccine approaches and to reach eradication goals is more urgent than previously believed. We closely analyse the flaws of various vaccine approaches, outline future directions and challenges that still face us and conclude that the focus of the field must be shifted to the basic research efforts including findings on the skin stage of infection. We also reflect on economic factors of vaccine development and the impact of public perception when it comes to vaccine uptake.
Biomedical Research ; Humans ; Malaria ; prevention & control ; Malaria Vaccines

Communicable diseases are a continuing menace to all people. Although some diseases have been conquered by antibiotics and vaccines, new ones are constantly emerging (such as HIV/AIDS, Legionnaires' disease), while others re-emerging (such as malaria, shigellosis). In 2000, the communicable disease control law had been amended to cope with emerging and re-emerging infectious diseases. The important amendatory contents are revision of statutory communicable diseases (3 class, 29 → 5 groups,63), shortening of the reporting time(group I,II,IV, immediately ; group III, V, within 7 days), and introduction of sentinel surveillance system, EDI reporting system, and reporting criteria.
Anti-Bacterial Agents ; Communicable Disease Control ; Communicable Diseases* ; Communicable Diseases, Emerging ; Jurisprudence ; Malaria ; Sentinel Surveillance ; Vaccines

Rhesus monkeys (5 in each group) were inoculated with recombinant fusion protein of cholera toxin B subunit and multi-valent epitopes of Plasmodium falciparum intranasal or intramuscular (i.m.). Immune-responses and protective effect were evaluated. The antibody titer (Geometry mean) against CTB reached 1:512 (intranasal) and 1:10000 (i.m.) 14 day after 3rd immunization, and antibodies against P. falciparum were also elucidated, the titers in i.m. group were also significantly higher than that in intranasal group. The monkeys were challenged with 1.25 x 10(8) sporozoites of P. cynomolgi, Patent infection was observed in all 5 monkeys in control group inoculated with PBS in 10 - 14 days after challenge. Patent infection was also observed in 5 animals inoculated via intranasal and 2 animals in intramuscular group 19th days after challenge, But the infection last only 4 days in 3 animals in intranasal group and 2 animals in intramuscular group. The results demonstrated that the vaccine candidate could induce protective immune-responses in rhesus monkey against the challenge of P. cynomolgi.
Animals ; Antibodies, Bacterial ; blood ; Antibodies, Protozoan ; blood ; Cholera Toxin ; genetics ; immunology ; Erythrocytes ; parasitology ; Macaca mulatta ; Malaria ; prevention & control ; veterinary ; Malaria Vaccines ; immunology ; Monkey Diseases ; prevention & control ; Plasmodium cynomolgi ; Plasmodium falciparum ; immunology ; Recombinant Fusion Proteins ; immunology ; Vaccines, Synthetic ; immunology

OBJECTIVETo study the expression of green fluorescent protein gene and immunogenicity of ES312 vaccine both mediated by Starburst polyamidoamine (PAMAM) dendrimers in vivo.

METHODSThe complex of green fluorescent protein or ES312 gene with Starburst PAMAM dendrimers were injected intramuscularly in Balb/c mice. The expression level and distribution of green fluorescent protein gene was detected by flow cytometer, Western blot and immunofluorescence assay. The immunogenicity of DNA vaccine was detected by enzyme-linked immunosorbent assay.

RESULTSThe expression of green fluorescent protein mediated by Starburst PAMAM dendrimers was found in heart, liver, spleen, lung, kidney, brain and injected muscle from 2 hours to 7 days after the vaccination. The highest expression level of the gene was detected in kidney, as well as in endothelial cells. The antibody response evoked by the DNA vaccine carried by the Starburst PAMAM dendrimers was significantly higher than that of the net DNA vaccination. Vaccination with Starburst PAMAM dendrimers elicited higher expression level of the gene in brain and kidney than with the net gene itself.

CONCLUSIONAs a novel non-viral DNA carrier with low self-antigenicity, Starburst PAMAM dendrimers have potential to mediate DNA transfer and expression in vivo.

Animals ; Biocompatible Materials ; pharmacology ; Dendrimers ; Drug Carriers ; pharmacology ; Female ; Green Fluorescent Proteins ; genetics ; pharmacokinetics ; Malaria Vaccines ; immunology ; Mice ; Mice, Inbred BALB C ; Polyamines ; pharmacology ; Vaccination ; Vaccines, DNA ; immunology

Vaccination against yellow fever is recommended for travelers to areas where yellow fever has been reported, and they should be vaccinated 10 days before the travel at an approved center for the vaccination. When traveling to areas where chloroquine-resistant P. falciparum has not been reported, once-a-week use of chloroquine alone is recommended, but when traveling to areas where chloroquineresistant P. falciparum has been reported, other agents such as mefloquine, doxycycline, atovaquone/proguanil and primaquine should be chosen. Other recommended immunizations are typhoid vaccine and hepatitis A/B vaccine. Traveler's diarrhea is one of the major health problems in terms of frequency, but antimicrobial prophylaxis is not routinely recommended.
Chloroquine ; Communicable Diseases* ; Diarrhea ; Doxycycline ; Hepatitis ; Immunization ; Malaria ; Mefloquine ; Primaquine ; Travel Medicine ; Typhoid-Paratyphoid Vaccines ; Vaccination ; Yellow Fever

Although the development of vaccines has been one of the most important contributions of immunology to medicine and public health, and despite vaccination having been proven as the most effective and cheapest medical practice to prevent infectious diseases, infectious diseases still remain the main cause of human deaths and new infectious diseases continue to emerge. Furthermore, we face an unprecedented succession of new pathogens able to jump species barriers and infect humans, even as we continue to be frustrated in our efforts to control devastating diseases such as HIV, malaria and tuberculosis. Hence the need to develop new vaccines and improve existing vaccines. Other challenges for scientists include rapid identification and response to emerging diseases and successful intervention in re-emerging infectious diseases. Remarkable progress in molecular biology and biotechnology is making possible the development and improvement of new and old vaccines. Recombinant DNA technology, genetic attenuation of viral and bacterial pathogens and their use as vectors for heterologous proteins, naked DNA vaccines and peptide vaccines represent the most popular approaches hitherto adopted. Reverse genetics and reverse vaccinology are now used to investigate new vaccines. Genome-based reverse vaccinology is very useful and a major tool in vaccine development. The rapid identification of the genome sequence to new pathogens enables the speedy development of diagnostic tools as well as recombinant expression of targets for vaccine. Strengthening research and development in vaccines, including international cooperation, may be the most effective next step to control and prevent infectious diseases worldwide.
Allergy and Immunology ; Biotechnology ; Communicable Diseases ; Communicable Diseases, Emerging* ; DNA, Recombinant ; Genome ; HIV ; Humans ; International Cooperation ; Malaria ; Molecular Biology ; Public Health ; Reverse Genetics ; Tuberculosis ; Vaccination ; Vaccines ; Vaccines, DNA ; Vaccines, Subunit

Development of an effective vaccine is critically needed for the prevention of malaria. One of the key antigens for malaria vaccines is the apical membrane antigen 1 (AMA-1) of the human malaria parasite Plasmodium falciparum, the surface protein for erythrocyte invasion of the parasite. The gene encoding AMA-1 has been sequenced from populations of P. falciparum worldwide, but the haplotype diversity of the gene in P. falciparum populations in the Greater Mekong Subregion (GMS), including Thailand, remains to be characterized. In the present study, the AMA-1 gene was PCR amplified and sequenced from the genomic DNA of 65 P. falciparum isolates from 5 endemic areas in Thailand. The nearly full-length 1,848 nucleotide sequence of AMA-1 was subjected to molecular analyses, including nucleotide sequence diversity, haplotype diversity and deduced amino acid sequence diversity and neutrality tests. Phylogenetic analysis and pairwise population differentiation (F( st) indices) were performed to infer the population structure. The analyses identified 60 single nucleotide polymorphic loci, predominately located in domain I of AMA-1. A total of 31 unique AMA-1 haplotypes were identified, which included 11 novel ones. The phylogenetic tree of the AMA-1 haplotypes revealed multiple clades of AMA-1, each of which contained parasites of multiple geographical origins, consistent with the F(st) indices indicating genetic homogeneity or gene flow among geographically distinct populations of P. falciparum in Thailand's borders with Myanmar, Laos and Cambodia. In summary, the study revealed novel haplotypes and population structure needed for the further advancement of AMA-1-based malaria vaccines in the GMS.
Amino Acid Sequence ; Base Sequence ; Cambodia ; DNA ; Erythrocytes ; Gene Flow ; Haplotypes ; Humans ; Laos ; Malaria ; Malaria Vaccines ; Membranes ; Myanmar ; Parasites ; Plasmodium falciparum ; Plasmodium ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Thailand ; Trees

OBJECTIVETo explore the characteristics of protective immunity against Plasmodium yoelii (P.y.) infection by asexual blood-stages cellular vaccine.

METHODSThe particulate vaccines were constructed by saponin or double-distilled-water lysed parasitic red blood cells and inoculated into BALB/c mice by intraperitoneal injection (i.p.). Each group was challenged by the lethal erythrocytic P.y. parasites, and then their parasitemia and survival rates were detected. Expressions of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) were detected by RT-PCR. ELISA showed the serum antibodies against the malaria challenge and their-subclasses. Special membrane protein was recognized by immunofluorescence assay.

RESULTSThe vaccination with saponified erythrocytic parasites protected the immunized mice against P.y. challenge, while double-distilled-water lysed vaccine did not (P < 0.01). This protection was characterized by the increase of both IFN-gamma/IgG2a and IL-4/IgG1. Meanwhile, MHC class I alpha chain molecule was recognized on the membrane of infected-erthythrocyte.

CONCLUSIONSaponified P.y. asexual blood-stage cellular vaccine has a significantly high protective immunity against this lethal P.y. malaria, and the immunity may be associated with the expression levels of IgG2a and IFN-gamma. MHC class I alpha chain on infected erythrocytes may play an important role in the successful immunization.

Animals ; Antibodies, Protozoan ; blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Histocompatibility Antigens Class I ; blood ; Immunoglobulin G ; blood ; Malaria ; prevention & control ; Malaria Vaccines ; immunology ; Mice ; Mice, Inbred BALB C ; Plasmodium yoelii ; immunology ; Random Allocation ; Vaccination

OBJECTIVETo test the immunity of peritoneal monocytes against Plasmodium yoelii infected red blood cells (target cells).

METHODSSaponinized Plasmodium yoelii infected red blood cells (SPRBC, Ghost erythrocyte) were used to immunize mice i.p twice. Three weeks later, the infected red blood cells were injected i.p.; 90 min later, the total peritoneal cells were isolated and washed for scanning electromicroscopy to observe the effects of the peritoneal monocyte to the target cell.

RESULTSThe peritoneal cells of the immunized mice were activated after 90 min of the challenge of target cells. The size of the cell was not even and the pili on the cell surface turned to be long and densed. Cell interconnections were found among the cells. In some peritoneal monocytes, their cell plasma were scattered (omlette-like) or with the shape as "cellular bomb". The scattered or the sheeted pili and spredding cell plasma could adhere to the target cells which were perforated densely and damaged.

CONCLUSIONThe protective adaptive immunity exists in the peritoneal monocytes of immunized mice.

Animals ; Antibodies, Protozoan ; immunology ; Erythrocyte Membrane ; parasitology ; Female ; Malaria Vaccines ; immunology ; Mice ; Mice, Inbred BALB C ; Monocytes ; immunology ; ultrastructure ; Peritoneum ; cytology ; Plasmodium yoelii ; immunology ; ultrastructure